Pipeline
Focused development,disciplined execution.
Our pipeline strategy focuses on the development of XenaGuides and advancement toward rapid clinical proof-of-concept.
Pipeline strategy
Move deliberatelyfrom evidence to execution.
Asset
Indication
Discovery
Lead
Optimization
Optimization
IND-Enabling
Phase 1
XBI-201*
Pancreatic Ductal
Adenocarcinoma
(PDAC)
XBI-101
Multiple Myeloma
(RRMM)
* Lead indication pancreatic cancer
Clinical Opportunity
Pancreatic Cancer
A solid tumor indication with substantial unmet need, limited durable options, and a significant global disease burden.
~500K
New global cases annually
3rd
Leading cause of U.S. cancer death
8-12 mo
Median metastatic survival
Pancreatic cancer carries one of oncology's most significant unmet needs, with limited durable options and a challenging tumor microenvironment.
The indication represents a meaningful expansion opportunity where patient outcomes remain poor and differentiated targeted approaches are urgently needed.
Opportunity focus
- High global incidence and mortality burden
- Limited durable options in metastatic disease
- Strong unmet need for differentiated targeted approaches
Every tumor has a signature. Xenagos finds it.
Opportunity to leverage XenaGuides across tumor types.